The Causes of Hypo- and Hyperphosphatemia in Humans

[1]  C. Roux,et al.  The Causes of Hypo- and Hyperphosphatemia in Humans , 2020, Calcified Tissue International.

[2]  M. Collins,et al.  Hyperphosphatemic Familial Tumoral Calcinosis , 2020, Definitions.

[3]  M. Fusaro,et al.  Phosphate and bone fracture risk in chronic kidney disease patients. , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  F. Anglani,et al.  Dent disease: A window into calcium and phosphate transport , 2019, Journal of cellular and molecular medicine.

[5]  Samson O Oyibo,et al.  Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction , 2019, Endocrinology, diabetes & metabolism case reports.

[6]  A. Folpe.  Phosphaturic mesenchymal tumors: A review and update. , 2019, Seminars in diagnostic pathology.

[7]  O. Mäkitie,et al.  FGF23 and its role in X-linked hypophosphatemia-related morbidity , 2019, Orphanet Journal of Rare Diseases.

[8]  E. Farrow,et al.  Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies , 2018, The Journal of clinical investigation.

[9]  Geert Carmeliet,et al.  Vitamin D insufficiency: Definition, diagnosis and management. , 2018, Best practice & research. Clinical endocrinology & metabolism.

[10]  M. Horwitz.  Non‐Parathyroid Hypercalcemia , 2018, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism.

[11]  J. Wetzels,et al.  Yield of diagnostic tests in unexplained renal hypophosphatemia: a case series , 2018, BMC Nephrology.

[12]  G. Fuleihan,et al.  Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature , 2018, Osteoporosis International.

[13]  S. Nasr,et al.  Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney—What We Know and What the Future May Hold , 2018, Current Hematologic Malignancy Reports.

[14]  H. Hakonarson,et al.  CYP3A4 mutation causes vitamin D–dependent rickets type 3 , 2018, The Journal of clinical investigation.

[15]  M. Vervloet,et al.  Prevention and treatment of hyperphosphatemia in chronic kidney disease. , 2018, Kidney international.

[16]  A. Folpe,et al.  Phosphaturic mesenchymal tumors: what an endocrinologist should know , 2018, Journal of Endocrinological Investigation.

[17]  T. Yoo,et al.  Phosphate is a potential biomarker of disease severity and predicts adverse outcomes in acute kidney injury patients undergoing continuous renal replacement therapy , 2018, PloS one.

[18]  J. Bilezikian,et al.  Hyperparathyroidism , 2018, The Lancet.

[19]  I. Macdougall,et al.  A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  Deborah J. Clegg,et al.  Electrolyte Disturbances in Patients with Chronic Alcohol‐Use Disorder , 2017, The New England journal of medicine.

[21]  K. White,et al.  Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics. , 2017, Bone.

[22]  E. Seeman,et al.  Serum 25-Hydroxyvitamin D Insufficiency in Search of a Bone Disease , 2017, The Journal of clinical endocrinology and metabolism.

[23]  B. Klarin,et al.  Analysis of Hypo- and Hyperphosphatemia in an Intensive Care Unit Cohort , 2017, Anesthesia and analgesia.

[24]  P. Courtoy,et al.  The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives , 2017, Nature Reviews Nephrology.

[25]  Manish Kaushik,et al.  Hypophosphatemia in critically ill patients with acute kidney injury treated with hemodialysis is associated with adverse events , 2017, Clinical kidney journal.

[26]  M. Seibel,et al.  Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature , 2017, Therapeutic advances in endocrinology and metabolism.

[27]  B. Knebelmann,et al.  Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients , 2017, Leukemia.

[28]  A. Folpe,et al.  Characterization of FN1–FGFR1 and novel FN1–FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors , 2016, Modern Pathology.

[29]  Dong Ki Kim,et al.  Electrolyte and mineral disturbances in septic acute kidney injury patients undergoing continuous renal replacement therapy , 2016, Medicine.

[30]  U. Pedersen-Bjergaard,et al.  NSAID‐induced symptomatic hypophosphataemia , 2016, British journal of clinical pharmacology.

[31]  K. Choate,et al.  Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment , 2016, Osteoporosis International.

[32]  D. Kahila,et al.  Observations of a large Dent disease cohort. , 2016, Kidney international.

[33]  M. Bouxsein,et al.  1,25‐Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  D. Siegel,et al.  Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era. , 2016, Journal of the American Society of Nephrology : JASN.

[35]  F. D. de Jongh,et al.  Hypophosphataemia due to FGF-23 producing B cell non-Hodgkin's lymphoma , 2016, BMJ Case Reports.

[36]  M. Whyte.  Hypophosphatasia — aetiology, nosology, pathogenesis, diagnosis and treatment , 2016, Nature Reviews Endocrinology.

[37]  D. Dempster,et al.  Presentation of Hypoparathyroidism: Etiologies and Clinical Features. , 2016, The Journal of clinical endocrinology and metabolism.

[38]  E. Brown,et al.  Epidemiology and Diagnosis of Hypoparathyroidism. , 2016, The Journal of clinical endocrinology and metabolism.

[39]  T. Magnuson,et al.  Vitamin D status and supplementation before and after bariatric surgery: a comprehensive literature review. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[40]  C. Roux,et al.  Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. , 2016, European journal of endocrinology.

[41]  M. Konrad,et al.  Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia. , 2016, Journal of the American Society of Nephrology : JASN.

[42]  D. Miao,et al.  CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. , 2016, The Journal of clinical investigation.

[43]  S. Johansson,et al.  Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications , 2015, European journal of endocrinology.

[44]  F. Granath,et al.  FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy. , 2016, Surgery.

[45]  L. Rejnmark,et al.  The Epidemiology of Nonsurgical Hypoparathyroidism in Denmark: A Nationwide Case Finding Study , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  Raghbir Kaur,et al.  Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease. , 2015, The Journal of clinical endocrinology and metabolism.

[47]  I. Endo,et al.  Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. , 2015, Endocrine journal.

[48]  M. Levine,et al.  CYP2R1 Mutations Impair Generation of 25-hydroxyvitamin D and Cause an Atypical Form of Vitamin D Deficiency. , 2015, The Journal of clinical endocrinology and metabolism.

[49]  L. Melton,et al.  Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010). , 2015, Bone.

[50]  Oren Steen,et al.  Role of Magnesium in Parathyroid Physiology , 2015 .

[51]  Z. Baloch,et al.  Parathyroids: Morphology and Pathology , 2015 .

[52]  J. Rogers,et al.  Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency , 2015, Supportive Care in Cancer.

[53]  F. Glorieux,et al.  Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome. , 2014, Bone.

[54]  Amita Sharma,et al.  Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. , 2014, Journal of the American Society of Nephrology : JASN.

[55]  Xiaobin Han,et al.  Osteocyte-Specific Deletion of Fgfr1 Suppresses FGF23 , 2014, PloS one.

[56]  M. Wolf,et al.  Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease , 2014, Current opinion in nephrology and hypertension.

[57]  G. Tonini,et al.  Denosumab for treatment of hypercalcemia of malignancy. , 2014, The Journal of clinical endocrinology and metabolism.

[58]  R. Unwin,et al.  Drug-induced renal Fanconi syndrome. , 2014, QJM : monthly journal of the Association of Physicians.

[59]  V. Nizet,et al.  Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis , 2014, Proceedings of the National Academy of Sciences.

[60]  R. Swaminathan,et al.  Phosphate homeostasis and disorders , 2014, Annals of clinical biochemistry.

[61]  V. Sreenivas,et al.  Expression of osteogenic molecules in the caudate nucleus and gray matter and their potential relevance for Basal Ganglia calcification in hypoparathyroidism. , 2014, The Journal of clinical endocrinology and metabolism.

[62]  E. Farrow,et al.  Neonatal Iron Deficiency Causes Abnormal Phosphate Metabolism by Elevating FGF23 in Normal and ADHR Mice , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[63]  S. Mane,et al.  Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. , 2014, Human molecular genetics.

[64]  P. Oefner,et al.  Mistargeting of peroxisomal EHHADH and inherited renal Fanconi's syndrome. , 2014, The New England journal of medicine.

[65]  B. Shields,et al.  The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a β cell phenotype , 2013, Journal of Medical Genetics.

[66]  S. Johansson,et al.  Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23–related hypophosphatemia, dental anomalies, and ectopic calcification , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[67]  J. Romijn,et al.  Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. , 2013, European journal of endocrinology.

[68]  D. Leaf,et al.  Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. , 2013, The Journal of clinical endocrinology and metabolism.

[69]  K. Whelan,et al.  Occurrence of refeeding syndrome in adults started on artificial nutrition support: prospective cohort study , 2013, BMJ Open.

[70]  Y. Liu,et al.  Hexa‐D‐arginine treatment increases 7B2•PC2 activity in hyp‐mouse osteoblasts and rescues the HYP phenotype , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[71]  H. Morgenstern,et al.  Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[72]  M. Collins,et al.  McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia , 2012, Orphanet Journal of Rare Diseases.

[73]  T. Baillie,et al.  An Inducible Cytochrome P450 3A4-Dependent Vitamin D Catabolic Pathway , 2012, Molecular Pharmacology.

[74]  D. Dinour,et al.  Renal disease with OCRL1 mutations: Dent-2 or Lowe syndrome? , 2012, Journal of Pediatric Genetics.

[75]  S. Papapoulos,et al.  Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism? , 2011, European journal of endocrinology.

[76]  P. Rowe.  Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. , 2012, Critical reviews in eukaryotic gene expression.

[77]  D. Chauveau,et al.  Impact of growth hormone hypersecretion on the adult human kidney. , 2011, Annales d'endocrinologie.

[78]  E. Farrow,et al.  Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice , 2011, Proceedings of the National Academy of Sciences.

[79]  L. Rejnmark,et al.  Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target‐organ involvement, treatment, and challenges for future research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[80]  E. Farrow,et al.  Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. , 2011, Bone.

[81]  S. Sereika,et al.  A 7‐day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[82]  L. Gesualdo,et al.  Rapamycin‐Induced Hypophosphatemia and Insulin Resistance Are Associated With mTORC2 Activation and Klotho Expression , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[83]  Corinne Stoetzel,et al.  Osteosclerotic bone dysplasia in siblings with a Fam20C mutation , 2011, Clinical genetics.

[84]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[85]  Huiliang Xie,et al.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. , 2011, Kidney international.

[86]  M. Whooley,et al.  Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[87]  H. Milionis,et al.  Medication-induced hypophosphatemia: a review. , 2010, QJM : monthly journal of the Association of Physicians.

[88]  D. Prié,et al.  Genetic disorders of renal phosphate transport. , 2010, The New England journal of medicine.

[89]  A. Sai,et al.  Vitamin D insufficiency, deficiency, and bone health. , 2010, The Journal of clinical endocrinology and metabolism.

[90]  D. Magen,et al.  A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome. , 2010, The New England journal of medicine.

[91]  T. Strom,et al.  Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. , 2010, American journal of human genetics.

[92]  V. Chalifa-Caspi,et al.  Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. , 2010, American journal of human genetics.

[93]  G. Rosa-Diez,et al.  Hyperphosphatemia after sodium phosphate laxatives in low risk patients: prospective study. , 2009, World journal of gastroenterology.

[94]  M. Econs,et al.  Hypophosphatemic rickets with hypercalciuria due to mutation in SLC34A3/type IIc sodium-phosphate cotransporter: presentation as hypercalciuria and nephrolithiasis. , 2009, The Journal of clinical endocrinology and metabolism.

[95]  C. Macica,et al.  Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp Mice , 2009, Calcified Tissue International.

[96]  A. Murthy.  X-linked hypophosphatemic rickets and craniosynostosis. , 2009, The Journal of craniofacial surgery.

[97]  T. K. Jensen,et al.  Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. , 2009, European journal of endocrinology.

[98]  H. Jüppner,et al.  Disorders of phosphate homeostasis and tissue mineralisation. , 2009, Endocrine development.

[99]  S. Ott.  Faculty Opinions recommendation of A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. , 2008 .

[100]  L. Churchill,et al.  Matrix extracellular phosphoglycoprotein inhibits phosphate transport. , 2008, Journal of the American Society of Nephrology : JASN.

[101]  B. Bammens,et al.  Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[102]  A. Prentice.  Vitamin D deficiency: a global perspective. , 2008, Nutrition reviews.

[103]  B. Gérard,et al.  NHERF1 mutations and responsiveness of renal parathyroid hormone. , 2008, The New England journal of medicine.

[104]  E. Donner,et al.  Linear nevus sebaceous syndrome: case reports and review of the literature. , 2008, Pediatric neurology.

[105]  E. Zackai,et al.  Mutations in FAM20C are associated with lethal osteosclerotic bone dysplasia (Raine syndrome), highlighting a crucial molecule in bone development. , 2007, American journal of human genetics.

[106]  M. McKee,et al.  Pyrophosphate Inhibits Mineralization of Osteoblast Cultures by Binding to Mineral, Up-regulating Osteopontin, and Inhibiting Alkaline Phosphatase Activity* , 2007, Journal of Biological Chemistry.

[107]  Siu L. Hui,et al.  FGF23 Concentrations Vary With Disease Status in Autosomal Dominant Hypophosphatemic Rickets , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[108]  A. Levin,et al.  Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. , 2007, Kidney international.

[109]  C. Peng,et al.  Acquired hypophosphatemia osteomalacia associated with Fanconi’s syndrome in Sjögren’s syndrome , 2007, Rheumatology International.

[110]  T. Strom,et al.  DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis , 2006, Nature Genetics.

[111]  L. Bonewald,et al.  Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism , 2006, Nature Genetics.

[112]  T. Strom,et al.  Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. , 2006, American journal of human genetics.

[113]  M. Bastepe,et al.  SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. , 2006, American journal of human genetics.

[114]  J. Mechanick,et al.  Effect of a Convenient Single 90-mg Pamidronate Dose on Biochemical Markers of Bone Metabolism in Patients With Acute Spinal Cord Injury , 2006, The journal of spinal cord medicine.

[115]  H. Tenenhouse,et al.  Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. , 2005, Endocrinology.

[116]  S. Sereika,et al.  Continuous PTH and PTHrP Infusion Causes Suppression of Bone Formation and Discordant Effects on 1,25(OH)2Vitamin D , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[117]  A. Meinders,et al.  Hypophosphatemia: an update on its etiology and treatment. , 2005, The American journal of medicine.

[118]  R. Kumar,et al.  "Phosphatonins" and the regulation of phosphorus homeostasis. , 2005, American journal of physiology. Renal physiology.

[119]  M. Marinella.  Refeeding Syndrome and Hypophosphatemia , 2005, Journal of intensive care medicine.

[120]  C. Wagner,et al.  Activation of dopamine D1-like receptors induces acute internalization of the renal Na+/phosphate cotransporter NaPi-IIa in mouse kidney and OK cells. , 2005, American journal of physiology. Renal physiology.

[121]  R. Shimkets,et al.  Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[122]  A. F. Stewart.  Clinical practice. Hypercalcemia associated with cancer. , 2005, The New England journal of medicine.

[123]  S. Ito,et al.  Adult onset Fanconi syndrome: extensive tubulo-interstitial lesions and glomerulopathy in the early stage of Chinese herbs nephropathy , 2004, Journal of Clinical and Experimental Nephrology.

[124]  T. Strom,et al.  FGF23 is processed by proprotein convertases but not by PHEX. , 2004, Bone.

[125]  P. Singer,et al.  Hypophosphatemia following open heart surgery: incidence and consequences. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[126]  Jeffrey B. Cheng,et al.  Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[127]  S. Trippel.  Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 5th ed. , 2004 .

[128]  Naveen D. Bhandarkar,et al.  Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. , 2004, The American journal of medicine.

[129]  E. Montgomery,et al.  Most Osteomalacia-associated Mesenchymal Tumors Are a Single Histopathologic Entity: An Analysis of 32 Cases and a Comprehensive Review of the Literature , 2004, The American journal of surgical pathology.

[130]  Y. Takeuchi,et al.  FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[131]  T. Verri,et al.  Thyroid hormone stimulation of Na/Pi-cotransport in opossum kidney cells , 1995, Pflügers Archiv.

[132]  R. Kumar,et al.  The phosphatonin pathway: new insights in phosphate homeostasis. , 2004, Kidney international.

[133]  M. Inouye,et al.  Regulation of intestinal NaPi-IIb cotransporter gene expression by estrogen. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[134]  T. Craig,et al.  Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. , 2003, The Journal of clinical investigation.

[135]  K. White,et al.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. , 2003, The Journal of clinical investigation.

[136]  R. Terkeltaub,et al.  Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification , 2003, Nature Genetics.

[137]  S. Fukumoto,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[138]  J. Adams,et al.  Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: A cause of vitamin D resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[139]  H. Izzedine,et al.  Drug-induced Fanconi's syndrome. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[140]  Y. Takeuchi,et al.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.

[141]  A. Mattu,et al.  Serum phosphate abnormalities in the emergency department. , 2002, The Journal of emergency medicine.

[142]  B. Gérard,et al.  Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. , 2002, The New England journal of medicine.

[143]  S. Shenolikar,et al.  Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[144]  T. Yoneya,et al.  Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. , 2002, Endocrinology.

[145]  H. Morris,et al.  Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. , 2002, Annual review of nutrition.

[146]  T. Komori,et al.  Dentin Matrix Protein 1 Is Predominantly Expressed in Chicken and Rat Osteocytes But Not in Osteoblasts , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[147]  M. Levi,et al.  Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. , 2001, Kidney international.

[148]  J. Pomposelli,et al.  Life‐threatening hypophosphatemia after right hepatic lobectomy for live donor adult liver transplantation , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[149]  R. Kumar,et al.  FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. , 2001, Biochemical and biophysical research communications.

[150]  J. Collins,et al.  Regulation of the human sodium-phosphate cotransporter NaP(i)-IIb gene promoter by epidermal growth factor. , 2001, American journal of physiology. Cell physiology.

[151]  T. Spector,et al.  The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. , 2001, The Journal of clinical endocrinology and metabolism.

[152]  K. Broman,et al.  Genetic and physical mapping of the locus for autosomal dominant renal Fanconi syndrome, on chromosome 15q15.3. , 2001, American journal of human genetics.

[153]  K. White,et al.  MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. , 2000, Genomics.

[154]  S. Deret,et al.  Adult Faconi Syndrome Secondary to Light Chain Gammopathy: Clinicopathologic Heterogeneity and Unnsual Features in 11 Patients , 2000, Medicine.

[155]  P. Schuff-Werner,et al.  Severe hypophosphatemia during hematopoietic reconstitution after allogeneic peripheral blood stem cell transplantation , 2000, Bone Marrow Transplantation.

[156]  C. Durbin,et al.  Oxford Textbook of Critical Care , 2000 .

[157]  J. Collins,et al.  Differential regulation of renal sodium-phosphate transporter by glucocorticoids during rat ontogeny. , 1999, American journal of physiology. Cell physiology.

[158]  E. Takeda,et al.  Regulation of intestinal Na+-dependent phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D3. , 1999, The Biochemical journal.

[159]  H. Murer,et al.  PTH-induced internalization of a type IIa Na/Pi cotransporter in OK-cells , 1999, Pflügers Archiv.

[160]  H. Tenenhouse,et al.  Effects of Npt2 gene ablation and low-phosphate diet on renal Na(+)/phosphate cotransport and cotransporter gene expression. , 1999, The Journal of clinical investigation.

[161]  G. Romieu,et al.  A Dose‐Finding Study of Zoledronate in Hypercalcemic Cancer Patients , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[162]  G. Peres,et al.  Vitamin D Status During Puberty in French Healthy Male Adolescents , 1999, Osteoporosis International.

[163]  M. Traebert,et al.  Regulation of small intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake. , 1999, The American journal of physiology.

[164]  M. Levi,et al.  Role of thyroid hormone in regulation of renal phosphate transport in young and aged rats. , 1999, Endocrinology.

[165]  M. Levi,et al.  Epidermal growth factor inhibits Na-Pi cotransport in weaned and suckling rats. , 1999, The American journal of physiology.

[166]  M. Traebert,et al.  Posttranscriptional regulation of the proximal tubule NaPi-II transporter in response to PTH and dietary Pi. , 1999, American journal of physiology. Renal physiology.

[167]  M. Levi,et al.  Regulation of renal phosphate transport by acute and chronic metabolic acidosis in the rat. , 1998, Kidney international.

[168]  S. Kato,et al.  Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. , 1998, The New England journal of medicine.

[169]  J. Silver,et al.  RNA-Protein Binding and Post-transcriptional Regulation of Parathyroid Hormone Gene Expression by Calcium and Phosphate* , 1998, The Journal of Biological Chemistry.

[170]  竹谷 豊.  Regulation of type II renal Na[+]-dependent inorganic phosphate transporters by 1,25-dihydroxyvitamin D3 , 1998 .

[171]  M. Speer,et al.  Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. , 1997, The Journal of clinical investigation.

[172]  M. Elisaf,et al.  MECHANISMS OF HYPOPHOSPHATAEMIA IN ALCOHOLIC PATIENTS , 1997, International journal of clinical practice.

[173]  J. Findling,et al.  Hypocalcemia and skeletal disease as presenting features of celiac disease. , 1997, Archives of internal medicine.

[174]  M. Berger,et al.  Exudative mineral losses after serious burns: a clue to the alterations of magnesium and phosphate metabolism. , 1997, The American journal of clinical nutrition.

[175]  C. Goodyer,et al.  Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice. , 1997, The Journal of clinical investigation.

[176]  M. Coulthard,et al.  A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. , 1996, The New England journal of medicine.

[177]  P. Marik,et al.  Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study. , 1996, Archives of surgery.

[178]  B. Clarke,et al.  Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features * , 1995, Clinical endocrinology.

[179]  J. Collins,et al.  Sodium-phosphate transporter adaptation to dietary phosphate deprivation in normal and hypophosphatemic mice. , 1995, The American journal of physiology.

[180]  H. Nakahama,et al.  Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. , 1995, Urologia internationalis.

[181]  M. J. Newman,et al.  The influence of acetazolamide and amlodipine on the intracellular sodium content of rat proximal tubular cells , 1994, British journal of pharmacology.

[182]  Glen R. Brown,et al.  Drug-and Nutrition-Induced Hypophosphatemia: Mechanisms and Relevance in the Critically Ill , 1994, The Annals of pharmacotherapy.

[183]  J. Kanis.  Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism , 1994 .

[184]  E. Bartoli,et al.  Renal tubular dysfunction in chronic alcohol abuse--effects of abstinence. , 1993, The New England journal of medicine.

[185]  A. Tolaymat,et al.  Idiopathic Fanconi syndrome in a family. Part I. Clinical aspects. , 1992, Journal of the American Society of Nephrology : JASN.

[186]  M. Merino,et al.  Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. , 1991, The New England journal of medicine.

[187]  S. Frostick,et al.  Hypophosphataemia after renal transplantation: relationship to immunosuppressive drug therapy and effects on muscle detected by 31P nuclear magnetic resonance spectroscopy. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[188]  M. Allon,et al.  Severe hypophosphatemia in hospitalized patients. , 1990, Mineral and electrolyte metabolism.

[189]  J. Laaban,et al.  Hypophosphatemia induced by mechanical ventilation in patients with chronic obstructive pulmonary disease. , 1989, Critical care medicine.

[190]  F. Ghishan,et al.  Phosphate transport in human jejunal brush-border membrane vesicles. , 1989, Gastroenterology.

[191]  U. Liberman,et al.  Elevated serum 1,25-dihydroxyvitamin D concentrations in siblings with primary Fanconi's syndrome. , 1988, The New England journal of medicine.

[192]  G. Lockitch,et al.  Age- and sex-specific pediatric reference intervals for biochemistry analytes as measured with the Ektachem-700 analyzer. , 1988, Clinical chemistry.

[193]  A. Brasier,et al.  Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. , 1988, The American journal of medicine.

[194]  U. Liberman,et al.  "Idiopathic" hypercalciuria and hereditary hypophosphatemic rickets. Two phenotypical expressions of a common genetic defect. , 1987, The New England journal of medicine.

[195]  U. Liberman,et al.  Hereditary hypophosphatemic rickets with hypercalciuria. , 1985, The New England journal of medicine.

[196]  M. Losowsky,et al.  A survey of vitamin D deficiency in gastrointestinal and liver disorders. , 1984, The Quarterly journal of medicine.

[197]  R. Kumar.  Hepatic and intestinal osteodystrophy and the hepatobiliary metabolism of vitamin D. , 1983, Annals of internal medicine.

[198]  S. Massry,et al.  On the mechanism of hypophosphatemia during acute hyperventilation: evidence for increased muscle glycolysis. , 1983, Mineral and electrolyte metabolism.

[199]  A. Norman,et al.  Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. , 1981, The New England journal of medicine.

[200]  T. Fujita,et al.  Adult-onset vitamin D-resistant osteomalacia with the unresponsiveness to parathyroid hormone. , 1980, The Journal of clinical endocrinology and metabolism.

[201]  H. DeLuca,et al.  Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. , 1978, The New England journal of medicine.

[202]  W. Wheeler,et al.  Effect of hypophosphatemia on myocardial performance in man. , 1977, The New England journal of medicine.

[203]  J. Knochel,et al.  The mechanism of hypophosphatemia in acute heat stroke. , 1977, JAMA.

[204]  M. Ravid,et al.  Proximal myopathy caused by latrogenic phosphate depletion. , 1976, JAMA.

[205]  O. Bijvoet,et al.  NOMOGRAM FOR DERIVATION OF RENAL THRESHOLD PHOSPHATE CONCENTRATION , 1975, The Lancet.

[206]  H. DeLuca,et al.  Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. , 1973, The New England journal of medicine.

[207]  A. Relman,et al.  Metabolic consequences of acid-base disorders. , 1972, Kidney international.

[208]  R. Pain,et al.  Hypophosphataemia and Hyperphosphataemia in a Hospital Population , 1972, British medical journal.

[209]  A. Marble,et al.  Serum phosphorus and potassium levels after intravenous administration of glucose; their use as diagnostic acids in diabetic and nondiabetic subjects with and without liver disease. , 1954, The New England journal of medicine.

[210]  D. Seldin,et al.  The metabolism of glucose and electrolytes in diabetic acidosis. , 1950, The Journal of clinical investigation.